Impacto de la terapia antirretroviral de alta eficacia en la respuesta clínica e inmunovirológica en enfermos SIDA

Se realizo un estudio propectivo y longitudinal con el proposito de evaluar la respuesta clinica, inmunologica y virologica de una cohorte de 34 enfermos de SIDA en la provincia de Cienfuegos tratados con terapia antirretroviral de alta eficacia (TARVAE). Del sexo masculino eran 67,6 por ciento y la media de edad 32 anos. La via de infeccion sexual se identifico en 91,2 por ciento. Del total de individuos, 79,4 por ciento definieron el SIDA por recuento de LTCD4+ A longitudinal prospective study was made to evaluate the clinical, immunological and virological response of a cohort of 34 AIDS patients in Cienfuegos provinces, who had been treated with highly active antiretroviral therapy (HAART). Males comprised 67.6percent of the total number and average age was 32 years. Sexual infection path was identified in 91.2 percent of cases. The CD4+ T counting under 200 cells defined AIDS in 79.4 percent of individuals. Twenty six patients suffered minor opportunistic infections (76.5 percent) whereas 32.4 percent got sick due to some major opportunistic disease prior to the therapy. After this therapy, these frequencies lowered to 20.6 percent and 11.8 percent respectively. Average CD4+ counting at the starting of HAART was 196 cell/mm3 and exceeded 400 cells in the rest of further countings. From a PVC average of 15 251 copies/ml one year after therapy, this figure reduced to 8 048 copies at 2 years. Only 10 cases required hospitalization after a HAART (29.4 percent). Treatment adherence reached over 80 persent and was correlated to immunological restoration. Survival after one year was 100 percent and only 2 patients died in the following 4 years. The positive impact of HAART on the frequency of opportunistic infections, immunological restoration and survival was proved.(AU)